secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytoDyn Inc. (CYDY)
CIK:        0001175680
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001558370-23-019285
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoDyn appoints Jacob Lalezari as interim CEO, effective Nov 17, 2023
----------------------------------------------------------------------

- Dr. Lalezari appointed interim CEO; Antonio Migliarese ceases interim President but remains CFO.
- Dr. Lalezari to receive only minimum salary required by law; no cash bonus, equity, or severance.
- CytoDyn has paid ~$1.5M to Lalezari's firm Quest Clinical Research since June 2021; $0.4M outstanding.
- Board seeks permanent CEO; Lalezari expected to serve a few months to resolve clinical hold and pursue partnerships.
- Dr. Lalezari previously served as interim CMO in 2020 and has advised the company for several years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/0001558370-23-019285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/cydy-20231117x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer